HomeCompareACUR vs NOBL

ACUR vs NOBL: Dividend Comparison 2026

ACUR yields 20000.00% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACUR wins by $52481917574412746752.00M in total portfolio value
10 years
ACUR
ACUR
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full ACUR calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — ACUR vs NOBL

📍 ACUR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACURNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACUR + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACUR pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACUR
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, ACUR beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACUR + NOBL for your $10,000?

ACUR: 50%NOBL: 50%
100% NOBL50/50100% ACUR
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ACUR right now

ACUR
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
-635.4
Piotroski
2/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACUR buys
0
NOBL buys
0
No recent congressional trades found for ACUR or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACURNOBL
Forward yield20000.00%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$52481917574412746752.00M$22.9K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$249.78
Total dividends collected$52448189483771600896.00M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ACUR vs NOBL ($10,000, DRIP)

YearACUR PortfolioACUR Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$2,010,700$2,000,000.00$10,917$217.08+$2.00MACUR
2$377,983,225$375,831,775.70$11,903$221.48+$377.97MACUR
3$66,433,479,469$66,029,037,418.28$12,962$225.68+$66433.47MACUR
4$10,916,985,471,987$10,845,901,648,955.73$14,099$229.68+$10916985.46MACUR
5$1,677,384,363,769,318$1,665,703,189,314,291.80$15,319$233.49+$1677384363.75MACUR
6$240,985,175,079,139,100$239,190,373,809,905,920.00$16,628$237.10+$240985175079.12MACUR
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$18,033$240.53+$32373573631143.68MACUR
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$19,539$243.78+$4066766648320630.00MACUR
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$21,154$246.86+$477730483406513344.00MACUR
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$22,884$249.78+$52481917574412746752.00MACUR

ACUR vs NOBL: Complete Analysis 2026

ACURStock

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.

Full ACUR Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this ACUR vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACUR vs SCHDACUR vs JEPIACUR vs OACUR vs KOACUR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.